Citations (109)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Aneta Myšková, David Sýkora, Jaroslav Kuneš & Lenka Maletínská. (2023) Lipidization as a tool toward peptide therapeutics. Drug Delivery 30:1.
Read now
Read now
Diego Pilati & Kenneth A. Howard. (2020) Albumin-based drug designs for pharmacokinetic modulation. Expert Opinion on Drug Metabolism & Toxicology 16:9, pages 783-795.
Read now
Read now
Emma Davé, Ralph Adams, Oliver Zaccheo, Bruce Carrington, Joanne E. Compson, Sarah Dugdale, Michael Airey, Sarah Malcolm, Hanna Hailu, Gavin Wild, Alison Turner, James Heads, Kaushik Sarkar, Andrew Ventom, Diane Marshall, Mark Jairaj, Tim Kopotsha, Louis Christodoulou, Miren Zamacona, Alastair D. Lawson, Sam Heywood & David P. Humphreys. (2016) Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. mAbs 8:7, pages 1319-1335.
Read now
Read now
Darrell Sleep. (2015) Albumin and its application in drug delivery. Expert Opinion on Drug Delivery 12:5, pages 793-812.
Read now
Read now
Kevin D. Niswender. (2011) Basal Insulin: Physiology, Pharmacology, and Clinical Implications. Postgraduate Medicine 123:4, pages 17-26.
Read now
Read now
Jean-Pierre Le Floch. (2010) Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes, Metabolic Syndrome and Obesity 3, pages 197-213.
Read now
Read now
Stephen Brunton. (2009) Implementing Treatment Guidelines for Type 2 Diabetes in Primary Care. Postgraduate Medicine 121:2, pages 125-138.
Read now
Read now
Athena Philis-Tsimikas. (2008) Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. Patient Preference and Adherence 2, pages 323-332.
Read now
Read now
Athena Philis-Tsimikas. (2008) An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). Expert Opinion on Pharmacotherapy 9:12, pages 2181-2195.
Read now
Read now
Rattan Juneja. (2008) Hyperglycemia Management in the Hospital: About Glucose Targets and Process Improvements. Postgraduate Medicine 120:4, pages 38-50.
Read now
Read now
Jean-Louis Selam, Christoph Koenen, Wayne Weng & Luigi Meneghini. (2008) Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Current Medical Research and Opinion 24:1, pages 11-20.
Read now
Read now
Donna L. Kerney, Diana Paradis & Stephen Brunton. (2007) Patient perceptions of insulin detemir as reported through patient telephone surveys. Current Medical Research and Opinion 23:9, pages 2043-2049.
Read now
Read now
Gregory E. Peterson. (2006) Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Current Medical Research and Opinion 22:12, pages 2613-2619.
Read now
Read now
Articles from other publishers (96)
Sijie Xian, Yuanhui Xiang, Dongping Liu, Bowen Fan, Katarína Mitrová, Rachel C. Ollier, Bo Su, Muhammad Ali Alloosh, Jiří Jiráček, Michael Sturek, Mouhamad Alloosh & Matthew J. Webber. (2023) Insulin–Dendrimer Nanocomplex for Multi‐Day Glucose‐Responsive Therapy in Mice and Swine. Advanced Materials.
Crossref
Crossref
Unnati Garg, Neha Jain, Shreya Kaul & Upendra Nagaich. (2023) Role of Albumin as a Targeted Drug Carrier in the Management of Rheumatoid Arthritis: A Comprehensive Review. Molecular Pharmaceutics 20:11, pages 5345-5358.
Crossref
Crossref
Haitao Hu, Anthony S. Ransdell, Hongchang Qu, Jim D. Durbin, Francisco A. Valenzuela, Selene Hernandez-Buquer & Malgorzata D. Gonciarz. (2023) Probing the Binding Mechanism of Acylated Peptides to Human Serum Albumin. ACS Chemical Biology 18:5, pages 1158-1167.
Crossref
Crossref
Xiufang Ding, Yue Wang, Sida Zhang, Ruihua Zhang, Dong Chen, Long Chen, Yu Zhang, Shi-Zhong Luo, Jianfu Xu & Chengxin Pei. (2023) Self-Assembly Nanostructure of Myristoylated ω-Conotoxin MVIIA Increases the Duration of Efficacy and Reduces Side Effects. Marine Drugs 21:4, pages 229.
Crossref
Crossref
Manjit & Brahmeshwar Mishra. 2023. Natural Polymeric Materials based Drug Delivery Systems in Lung Diseases. Natural Polymeric Materials based Drug Delivery Systems in Lung Diseases
25
59
.
Mutasem Rawas-Qalaji, Hnin Ei Thu & Zahid Hussain. (2022) Oromucosal delivery of macromolecules: Challenges and recent developments to improve bioavailability. Journal of Controlled Release 352, pages 726-746.
Crossref
Crossref
Hanhee Cho, Seong Ik Jeon, Cheol-Hee Ahn, Man Kyu Shim & Kwangmeyung Kim. (2022) Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation. Pharmaceutics 14:4, pages 728.
Crossref
Crossref
Florian Brandt, Martin Ullrich, Markus Laube, Klaus Kopka, Michael Bachmann, Reik Löser, Jens Pietzsch, Hans-Jürgen Pietzsch, Jörg van den Hoff & Robert Wodtke. (2021) “Clickable” Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. Journal of Medicinal Chemistry 65:1, pages 710-733.
Crossref
Crossref
Xinxin Gao, Ann De Mazière, Rhiannon Beard, Judith Klumperman & Rami N. Hannoush. (2021) Fatty acylation enhances the cellular internalization and cytosolic distribution of a cystine-knot peptide. iScience 24:11, pages 103220.
Crossref
Crossref
Cláudia Azevedo, Soraia Pinto, Sopisa Benjakul, Jeannette Nilsen, Hélder A. Santos, Giovanni Traverso, Jan Terje Andersen & Bruno Sarmento. (2021) Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery. Advanced Drug Delivery Reviews 175, pages 113778.
Crossref
Crossref
Caitlin L. Maikawa, Andrea I. d’Aquino, Rayhan A. LalBruce A. Buckingham & Eric A. Appel. (2021) Engineering biopharmaceutical formulations to improve diabetes management. Science Translational Medicine 13:578.
Crossref
Crossref
Saad Tayyab & Shevin Rizal Feroz. 2021.
193
218
.
Priyanka Maurya, Samipta Singh, Nidhi Mishra, Raviraj Pal, Neelu Singh, Poonam Parashar & Shubhini A. Saraf. 2021. Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications. Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications
465
496
.
Sung-Hyun Yang, Connor A. Clemett, Margaret A. Brimble, Simon J. O'Carroll & Paul W. R. Harris. (2020)
Synthesis and biological evaluation of
S
-lipidated lipopeptides of a connexin 43 channel inhibitory peptide
. RSC Medicinal Chemistry 11:9, pages 1041-1047.
Crossref
Crossref
So Yeon Cho, Jaekyu Han, Sang-Hoon Cha & Sung-il Yoon. (2020) Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics. Biochemical and Biophysical Research Communications 526:4, pages 941-946.
Crossref
Crossref
Angelina Mimoun, Sandrine Delignat, Ivan Peyron, Victoria Daventure, Maxime Lecerf, Jordan D. Dimitrov, Srinivas V. Kaveri, Jagadeesh Bayry & Sébastien Lacroix-Desmazes. (2020) Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Frontiers in Immunology 11.
Crossref
Crossref
Thazha P Prakash, Adam E Mullick, Richard G Lee, Jinghua Yu, Steve T Yeh, Audrey Low, Alfred E Chappell, Michael E Østergaard, Sue Murray, Hans J Gaus, Eric E Swayze & Punit P Seth. (2019) Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Research 47:12, pages 6029-6044.
Crossref
Crossref
S. Sh. Gapizov, L. E. Petrovskaya, L. N. Shingarova, E. A. Kryukova, E. F. Boldyreva, E. P. Lukashev, S. A. Yakimov, E. V. Svirshchevskaya, D. A. Dolgikh & M. P. Kirpichnikov. (2019) Fusion with an albumin‐binding domain improves pharmacokinetics of an αvβ3‐integrin binding fibronectin scaffold protein. Biotechnology and Applied Biochemistry 66:4, pages 617-625.
Crossref
Crossref
Lotte Bjerre Knudsen & Jesper Lau. (2019) The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology 10.
Crossref
Crossref
Joseph Lau, Orit Jacobson, Gang Niu, Kuo-Shyan Lin, François Bénard & Xiaoyuan Chen. (2019) Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjugate Chemistry 30:3, pages 487-502.
Crossref
Crossref
Elyse T. Williams, Paul W. R. Harris, Muhammad A. Jamaluddin, Kerry M. Loomes, Debbie L. Hay & Margaret A. Brimble. (2018) Solid‐Phase Thiol–Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist. Angewandte Chemie International Edition 57:36, pages 11640-11643.
Crossref
Crossref
Elyse T. Williams, Paul W. R. Harris, Muhammad A. Jamaluddin, Kerry M. Loomes, Debbie L. Hay & Margaret A. Brimble. (2018) Solid-Phase Thiol-Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist. Angewandte Chemie 130:36, pages 11814-11817.
Crossref
Crossref
Thomas Forst. (2018) Möglichkeiten und Grenzen der aktuellen Insulintherapie. CME 15:1-2, pages 55-63.
Crossref
Crossref
Seung R. Hwang & Jin W. Park. 2018. Emerging Areas in Bioengineering. Emerging Areas in Bioengineering
645
654
.
Thomas Forst. (2017) Möglichkeiten und Grenzen der aktuellen Insulintherapie. Info Diabetologie 11:6, pages 37-45.
Crossref
Crossref
Michael Lykke Hvam, Yunpeng Cai, Frederik Dagnæs-Hansen, Jesper Sejrup Nielsen, Jesper Wengel, Jørgen Kjems & Kenneth A. Howard. (2017) Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. Molecular Therapy 25:7, pages 1710-1717.
Crossref
Crossref
Wenhui Wei, Jenny Jiang, Youbei Lou, Sohini Ganguli & Mark S. Matusik. (2017) Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments. Journal of Managed Care & Specialty Pharmacy 23:3, pages 278-290.
Crossref
Crossref
Morten Schlein. (2016) Insulin Formulation Characterization—the Thioflavin T Assays. The AAPS Journal 19:2, pages 397-408.
Crossref
Crossref
Renata Kowalczyk, Paul W. R. Harris, Geoffrey M. Williams, Sung-Hyun Yang & Margaret A. Brimble. 2017. Peptides and Peptide-based Biomaterials and their Biomedical Applications. Peptides and Peptide-based Biomaterials and their Biomedical Applications
185
227
.
Maja Thim Larsen, Matthias Kuhlmann, Michael Lykke Hvam & Kenneth A. Howard. (2016) Albumin-based drug delivery: harnessing nature to cure disease. Molecular and Cellular Therapies 4:1.
Crossref
Crossref
Konrad Bienk, Michael Lykke Hvam, Malgorzata Maria Pakula, Frederik Dagnæs-Hansen, Jesper Wengel, Birgitte Mølholm Malle, Ulrich Kragh-Hansen, Jason Cameron, Jens Thostrup Bukrinski & Kenneth A. Howard. (2016) An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. Journal of Controlled Release 232, pages 143-151.
Crossref
Crossref
João Pedro Martins, Patrick J. Kennedy, Hélder A. Santos, Cristina Barrias & Bruno Sarmento. (2016) A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacology & Therapeutics 161, pages 22-39.
Crossref
Crossref
Dorthe Viuff, Filipa Antunes, Leslie Evans, Jason Cameron, Hans Dyrnesli, Birgitte Thue Ravn, Magnus Stougaard, Kader Thiam, Birgitte Andersen, Søren Kjærulff & Kenneth A. Howard. (2016) Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. Journal of Controlled Release 223, pages 22-30.
Crossref
Crossref
Mark A. Atkinson. 2016. Williams Textbook of Endocrinology. Williams Textbook of Endocrinology
1451
1483
.
Malin Bern, Kine Marita Knudsen Sand, Jeannette Nilsen, Inger Sandlie & Jan Terje Andersen. (2015) The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. Journal of Controlled Release 211, pages 144-162.
Crossref
Crossref
Kenneth A Howard. (2015) Albumin: the next-generation delivery technology. Therapeutic Delivery 6:3, pages 265-268.
Crossref
Crossref
Kine Marita Knudsen Sand, Malin Bern, Jeannette Nilsen, Hanna Theodora Noordzij, Inger Sandlie & Jan Terje Andersen. (2015) Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Frontiers in Immunology 5.
Crossref
Crossref
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle & Matthew C. Riddle. (2014) New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care 37:12, pages 3235-3243.
Crossref
Crossref
A. J. Garber. (2014) Will the next generation of basal insulins offer clinical advantages?. Diabetes, Obesity and Metabolism 16:6, pages 483-491.
Crossref
Crossref
Priyanka Murawala, Amruta Tirmale, Anjali Shiras & B.L.V. Prasad. (2014) In situ synthesized BSA capped gold nanoparticles: Effective carrier of anticancer drug Methotrexate to MCF-7 breast cancer cells. Materials Science and Engineering: C 34, pages 158-167.
Crossref
Crossref
Darrell Sleep, Jason Cameron & Leslie R. Evans. (2013) Albumin as a versatile platform for drug half-life extension. Biochimica et Biophysica Acta (BBA) - General Subjects 1830:12, pages 5526-5534.
Crossref
Crossref
André M. M. Miltenburg, Marita Prohn, Jacqueline H. M. van Kuijk, Renger G. Tiessen, Martin de Kort & Rob J. W. Berg. (2013)
Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier
®
insulin
. British Journal of Clinical Pharmacology 75:5, pages 1221-1230.
Crossref
Crossref
Geralyn R. Spollett. (2012) Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered?. Journal of the American Academy of Nurse Practitioners 24, pages 249-259.
Crossref
Crossref
Alexey A. Poyarkov, Svetlana A. Poyarkova, Irina V. Smirnova & Valery P. Kukhar. (2012) Liporetro-D-peptides - A novel class of highly selective thrombin inhibitors. Thrombosis Research 129:4, pages e97-e105.
Crossref
Crossref
Carla A. Borgoño & Bernard Zinman. (2012) Insulins: Past, Present, and Future. Endocrinology and Metabolism Clinics of North America 41:1, pages 1-24.
Crossref
Crossref
Jan Terje Andersen & Inger Sandlie. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
85
120
.
R. Keith Campbell. (2011) Hospital Strategies for Insulin Therapy with Rapid-Acting Insulin Analogs. Hospital Pharmacy 46:8, pages 580-590.
Crossref
Crossref
David R. Owens. (2011) Insulin Preparations with Prolonged Effect. Diabetes Technology & Therapeutics 13:S1, pages S-5-S-14.
Crossref
Crossref
Ronald R Bowsher & William L Nowatzke. (2011) Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods. Bioanalysis 3:8, pages 883-898.
Crossref
Crossref
George S. Eisenbarth & John B. Buse. 2011. Williams Textbook of Endocrinology. Williams Textbook of Endocrinology
1436
1461
.
S. Arnolds, B. Kuglin, C. Kapitza & T. Heise. (2010) How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. International Journal of Clinical Practice 64:10, pages 1415-1424.
Crossref
Crossref
Eva Horn Moeller, Birgitte Holst, Line Hagner Nielsen, Pia Steen Pedersen & Jesper Østergaard. (2010) Stability, liposome interaction, and in vivo pharmacology of ghrelin in liposomal suspensions. International Journal of Pharmaceutics 390:1, pages 13-18.
Crossref
Crossref
N I Berbovaia. (2010) Long-acting insulin analogues: comparative characteristics of their structure, pharmacological properties, and potential for clinical application. Problems of Endocrinology 56:2, pages 64-71.
Crossref
Crossref
Luigi Meneghini, Andreas Liebl & Martin J. Abrahamson. (2010) Insulin detemir: A historical perspective on a modern basal insulin analogue. Primary Care Diabetes 4, pages S31-S42.
Crossref
Crossref
P. M. Szumita. (2009) The hospital pharmacist: an integral part of the hyperglycaemic management team. Journal of Clinical Pharmacy and Therapeutics 34:6, pages 613-621.
Crossref
Crossref
M. Marre, M. Pinget, H. Gin, C. Thivolet, H. Hanaire, J.-J. Robert & P. Fontaine. (2009) Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE™ study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes & Metabolism 35:6, pages 469-475.
Crossref
Crossref
Scott Drab. (2009) Translating clinical guidelines into clinical practice: Role of the pharmacist in type 2 diabetes management. Journal of the American Pharmacists Association 49:6, pages e152-e162.
Crossref
Crossref
Leo Niskanen, Antti Virkamäki, Jes B. Hansen & Tero Saukkonen. (2009) Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: Evidence from the PREDICTIVE™ study. Diabetes Research and Clinical Practice 86:2, pages e15-e18.
Crossref
Crossref
V. Arutchelvam, T. Heise, S. Dellweg, B. Elbroend, I. Minns & P. D. Home. (2009) Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins. Diabetic Medicine 26:10, pages 1027-1032.
Crossref
Crossref
Lisa Kroon. (2009) Overview of insulin delivery pen devices. Journal of the American Pharmacists Association 49:5, pages e118-e131.
Crossref
Crossref
E. Mandosi, M. Fallarino, M. Rossetti, A. Gatti & S. Morano. (2009) Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH. Diabetes Research and Clinical Practice 84:2, pages e18-e20.
Crossref
Crossref
Pierre Fontaine, Henri Gin, Michel Pinget, Charles Thivolet, Hélène Hanaire, Jean-Jacques Robert, Michel Marre & Srishyla Venkatanarasimhachar. (2009) Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Advances in Therapy 26:5, pages 535-551.
Crossref
Crossref
Jean-Louis Selam & Luigi F. Meneghini. (2009) Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. Advances in Therapy 26:2, pages 194-207.
Crossref
Crossref
Jean-Pierre Le Floch, Marc Lévy, Helen Mosnier-Pudar, Frank Nobels, Sylvie Laroche, Sophie Gonbert, Eveline Eschwege & Pierre Fontaine. (2009) Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes. Diabetes Care 32:1, pages 32-37.
Crossref
Crossref
Jan Terje Andersen & Inger Sandlie. (2009) The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation: Implications for Development of New Diagnostics and Therapeutics. Drug Metabolism and Pharmacokinetics 24:4, pages 318-332.
Crossref
Crossref
Michael E Cobble. (2009) Initiating and Intensifying Insulin Therapy for Type 2 Diabetes: Why, When, and How. American Journal of Therapeutics 16:1, pages 56-64.
Crossref
Crossref
L. Tapia Ceballos. (2009) Nuevas insulinas. Actualización. Anales de Pediatría 70:1, pages 65-71.
Crossref
Crossref
Thuan B. Nguyen, E. V. K. Suresh Kumar, Diptesh Sil, Stewart J. Wood, Kelly A. Miller, Hemamali J. Warshakoon, Apurba Datta & Sunil A. David. (2008) Controlling Plasma Protein Binding: Structural Correlates of Interactions of Hydrophobic Polyamine Endotoxin Sequestrants with Human Serum Albumin. Molecular Pharmaceutics 5:6, pages 1131-1137.
Crossref
Crossref
Felix Kratz. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release 132:3, pages 171-183.
Crossref
Crossref
Anja Böhm, Harald Staiger, Anita M. Hennige, Carina Haas, Fausto Machicao & Hans-Ulrich Häring. (2008) Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis. Regulatory Peptides 151:1-3, pages 160-163.
Crossref
Crossref
William C. Gong. (2012) Determining Effective Insulin Analog Therapy Based on the Individualized Needs of Patients with Type 2 Diabetes Mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:10, pages 1299-1308.
Crossref
Crossref
Pedro Iglesias & Juan J. Díez. (2008) Insulin therapy in renal disease. Diabetes, Obesity and Metabolism 10:10, pages 811-823.
Crossref
Crossref
Satish K. GargRamachandra G. Naik. (2008) Long-Acting Insulin Analogs Versus Human Insulins. Diabetes Technology & Therapeutics 10:5, pages 331-332.
Crossref
Crossref
D.R. OwensG.B. Bolli. (2008) Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application. Diabetes Technology & Therapeutics 10:5, pages 333-349.
Crossref
Crossref
Carolyn Robertson. (2008) Translating ADA/EASD Guidelines and the ACE/AACE Road Maps into Primary Care of Patients with Type 2 Diabetes. The Journal for Nurse Practitioners 4:9, pages 661-671.
Crossref
Crossref
Martin de Kort, Bas Gianotten, Jeffry A. J. Wisse, Ebo S. Bos, Michel H. M. Eppink, Ellen Mattaar, Gerard M. T. Vogel, Wim H. A. Dokter, Maarten Honing, Stanislava Vonsovic, Martin-Jan Smit, Jac C. H. M. Wijkmans & Constant A. A. van Boeckel. (2008) Conjugation of ATIII-Binding Pentasaccharides to Extend the Half-Life of Proteins: Long-Acting Insulin. ChemMedChem 3:8, pages 1189-1193.
Crossref
Crossref
Melanie J. DaviesTadeusz DerezinskiClaus Bang PedersenPer Clauson. (2008) Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia. Diabetes Technology & Therapeutics 10:4, pages 273-277.
Crossref
Crossref
Arturo Rolla. (2008) Pharmacokinetic and Pharmacodynamic Advantages of Insulin Analogues and Premixed Insulin Analogues Over Human Insulins: Impact on Efficacy and Safety. The American Journal of Medicine 121:6, pages S9-S19.
Crossref
Crossref
Steven Leichter. (2008) Is the use of insulin analogues cost-effective?. Advances in Therapy 25:4, pages 285-299.
Crossref
Crossref
J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen & G. Schernthaner. (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51:3, pages 408-416.
Crossref
Crossref
Luigi F. Meneghini. (2008) Clarification of the Similarities and Differences Among Insulin Analog Preparations: Response to Becker. Diabetes Technology & Therapeutics 10:1, pages 51-53.
Crossref
Crossref
Francesca Porcellati, Paolo Rossetti, Natalia Ricci Busciantella, Stefania Marzotti, Paola Lucidi, Steven Luzio, David R. Owens, Geremia B. Bolli & Carmine G. Fanelli. (2007) Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes. Diabetes Care 30:10, pages 2447-2452.
Crossref
Crossref
Martha M. Funnell. (2007) Insulin detemir: A new option for the treatment of diabetes. Journal of the American Academy of Nurse Practitioners 19:10, pages 508-515.
Crossref
Crossref
T. Heise & T. R. Pieber. (2007) Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes, Obesity and Metabolism 9:5, pages 648-659.
Crossref
Crossref
Anne Daly. (2007) Use of Insulin and Weight Gain: Optimizing Diabetes Nutrition Therapy. Journal of the American Dietetic Association 107:8, pages 1386-1393.
Crossref
Crossref
Joseph Tibaldi. (2007) Actions of insulin beyond glycemic control: A perspective on insulin detemir. Advances in Therapy 24:4, pages 868-882.
Crossref
Crossref
H.-J. Lüddeke, S. Sreenan, S. Aczel, S. Maxeiner, M. Yenigun, P. Kozlovski, H. Gydesen & A. Dornhorst. (2007) PREDICTIVE? ? a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes, Obesity and Metabolism 9:3, pages 428-434.
Crossref
Crossref
Reinhard H.A. Becker. (2007) Insulin Glulisine Complementing Basal Insulins: A Review of Structure and Activity. Diabetes Technology & Therapeutics 9:1, pages 109-121.
Crossref
Crossref
Katarina Ra??lov??Soren Can Tamer, Per Clauson & Diane Karl. (2007) Insulin Detemir Results in Less Weight Gain than NPH Insulin When??Used in Basal-Bolus Therapy for??Type??2 Diabetes??Mellitus, and this??Advantage Increases with Baseline??Body??Mass Index. Clinical Drug Investigation 27:4, pages 279-285.
Crossref
Crossref
Javier Morales. (2007) Defining the Role of Insulin Detemir in Basal Insulin Therapy. Drugs 67:17, pages 2557-2584.
Crossref
Crossref
Sten Madsbad. 2007. Pharmacotherapy of Diabetes: New Developments. Pharmacotherapy of Diabetes: New Developments
53
65
.
Mads Krogsgaard Thomsen. 2007. Pharmacotherapy of Diabetes: New Developments. Pharmacotherapy of Diabetes: New Developments
273
276
.
Danilo Verge. (2006) Innovative solutions for diabetes therapy. Diabetes Research and Clinical Practice 74, pages S148-S151.
Crossref
Crossref
Gary Walsh & Roy Jefferis. (2006) Post-translational modifications in the context of therapeutic proteins. Nature Biotechnology 24:10, pages 1241-1252.
Crossref
Crossref
Athena Philis-Tsimikas, Guillaume Charpentier, Per Clauson, Gabriela Martinez Ravn, Victor Lawrence Roberts & Birger Thorsteinsson. (2006) Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes. Clinical Therapeutics 28:10, pages 1569-1581.
Crossref
Crossref
John M. Beals & Armen B. Shanafelt. (2006) Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies 3:1, pages 87-94.
Crossref
Crossref